Resideo Reports Strong Q4 & Full-Year 2025 Adjusted Results, Exceeding Outlooks, and Initiates Positive 2026 Guidance
Summary
Resideo Technologies announced strong fourth quarter and full-year 2025 financial results, with key adjusted metrics exceeding or meeting the high end of their outlook, and provided an optimistic 2026 financial outlook.
Key Events
-
Exceeded 2025 Outlooks
Reported record high full-year 2025 net revenue of $7.47 billion, Adjusted EBITDA of $833 million, and Adjusted EPS of $2.68, all exceeding the high end of previous guidance.
-
Q4 2025 Performance Beat Expectations
Fourth quarter net revenue of $1.895 billion and Adjusted EBITDA of $226 million surpassed the high end of the company's outlook range.
-
Strategic Indemnification Agreement Termination
Full-year GAAP net loss of $527 million was primarily due to a $972 million expense for terminating the Indemnification Agreement with Honeywell, a move expected to de-risk the company long-term.
-
Initiated Positive 2026 Outlook
Provided full-year 2026 guidance projecting net revenue between $7.8 billion and $7.9 billion, and Adjusted EPS between $3.00 and $3.20.
Analysis
The company reported record high full-year 2025 net revenue, Adjusted EBITDA, and Adjusted EPS, all surpassing their previous outlooks. While a GAAP net loss was recorded for the full year, it was primarily driven by a significant one-time expense related to the termination of the Indemnification Agreement with Honeywell, a strategic move expected to benefit the company long-term. The strong adjusted performance and positive 2026 guidance, including projected revenue of $7.8-$7.9 billion and Adjusted EPS of $3.00-$3.20, indicate solid operational execution and a favorable outlook. Investors should note the company's mention of an anticipated separation of its Products & Solutions and ADI Global Distribution businesses, which could unlock further value.
At the time of this filing, REZI was trading at $35.72 on NYSE in the Trade & Services sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $14.18 to $45.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.